Bayer's Hemophilia A Portfolio Boosted by Jivi's EU Approval

 
• By Sten Stovall

EU approval and coming launch there of Jivi will complement Bayer's two existing Factor VIII treatments, Kogenate and its successor Kovaltry.

Protein
Jivi is a longer-acting Factor VIII therapy designed to cut the number of infusions needed • Source: Shutterstock

More from New Products

More from Scrip